Curanex Pharmaceuticals Inc Common Stock
CURX
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.53M
Close$
$0.18
17.3% downside
Current Fair Value
17.3% downsideOvervalued by 17.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.53 Million |
|---|---|
| Enterprise Value | $1.82 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.17 |
| Beta | -2.74 |
| Outstanding Shares | 28,344,545 |
Return
| Return on Equity | -129.58% |
|---|---|
| Return on Assets | -124.46% |
| Return on Invested Capital | -127.01% |
Valuation & Multiples
| P/E Ratio | -0.72 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.16%▼ 0.51% |
|---|---|
| Total Invested | $167,578▲ 19.30% |
| Investors Holding | 8▼ 3.00% |
ESG Score
No data
About Curanex Pharmaceuticals Inc Common Stock
CEO: Jun Liu Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas,...